Pages that link to "Q74395587"

The following pages link to Luana Calabro' (Q74395587):

Displaying 39 items.

• Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. (Q33396664) (← links)
• Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. (Q33643902) (← links)
• Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma (Q34656538) (← links)
• Epigenetic immunomodulation of hematopoietic malignancies. (Q36279341) (← links)
• Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. (Q36293343) (← links)
• Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. (Q36801625) (← links)
• Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy (Q37681718) (← links)
• Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond. (Q38050835) (← links)
• CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? (Q38252348) (← links)
• Immune checkpoint blockade in malignant mesothelioma (Q38475077) (← links)
• Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. (Q38669328) (← links)
• Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? (Q38717244) (← links)
• Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. (Q39500230) (← links)
• ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. (Q39873712) (← links)
• Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. (Q40124768) (← links)
• Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. (Q40163076) (← links)
• Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). (Q40164620) (← links)
• Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. (Q40408299) (← links)
• Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. (Q40511605) (← links)
• Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". (Q43127268) (← links)
• Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. (Q43175108) (← links)
• Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. (Q43176112) (← links)
• Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial (Q44807139) (← links)
• Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain. (Q45061050) (← links)
• Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. (Q47646115) (← links)
• Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study (Q48401064) (← links)
• Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. (Q50191687) (← links)
• Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). (Q51738566) (← links)
• New horizons from immunotherapy in malignant pleural mesothelioma. (Q52672888) (← links)
• Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. (Q52758918) (← links)
• Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. (Q52777255) (← links)
• Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences (Q56893769) (← links)
• Biomarkers for immune checkpoint inhibitors – Authors' reply (Q57570287) (← links)
• Differential levels of soluble endoglin (CD105) in myeloid malignancies (Q57570380) (← links)
• Circulating haemopoietic and endothelial progenitor cells are decreased in COPD (Q60188620) (← links)
• Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukaemia and essential thrombocythaemia (Q60456330) (← links)
• Soluble angiogenic factors: implications for chronic myeloproliferative disorders (Q77759516) (← links)
• Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin (Q80180031) (← links)
• Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy (Q91723296) (← links)